Utilizing the GLP-1 signaling system to treat diabetes: Sorting through the pharmacologic approaches
- 45 Downloads
cagon-like peptide-1 (GLP-1) is an intestinal hormone that promotes glucose homeostasis through the regulation of insulin and glucagon secretion, gastric emptying, and food intake. This spectrum of effects makes GLP-1 an attractive candidate for drug development. However, because GLP-1 is a small peptide with rapid metabolism in the circulation, its usefulness to treat patients is limited. However, GLP-1 mimetics that are resistant to degradation have been developed and are effective in lowering blood glucose in diabetic patients. A second strategy for harnessing GLP-1 therapeutically is to inhibit the metabolism of endogenous GLP-1; several orally available compounds are in clinical trials. These two new classes of drugs both enhance GLP-1 signaling but differ in several key characteristics that may lead to distinct roles in the treatment of diabetic patients.
KeywordsMetformin Liraglutide Exenatide Gastric Inhibitory Polypeptide Dipeptidyl Peptidase
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 26.Wang X, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic betacells by a cyclic adenosine monophosphate/protein kinase Adependent mechanism. Endocrinology 2001, 142:1820–1827.PubMedCrossRefGoogle Scholar
- 36.Nikolaidis LA, Mankad S, Sokos GG, et al.: Effects of glucagonlike peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962–965. Describes a small clinical study in which patients having an angioplasty following acute myocardial infarction were treated with 72-hour infusions of recombinant GLP-1. Compared to control subjects with comparable cardiac events that GLP-1 treated, patients had significant improvements in cardiac function. This is the first demonstration of acute effects of GLP-1 on the human heart; it is consistent with animal data suggesting improvement in myocardial metabolism with GLP-1.PubMedCrossRefGoogle Scholar
- 43.Degn KB, Brock B, Juhl CB, et al.: Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004, 53:2397–2403. An excellent clinical study demonstrating that despite increasing insulin secretion rates under basal conditions, exenatide does not affect the coordinated endocrine response to hypoglycemia.PubMedCrossRefGoogle Scholar
- 48.Kendall DM, Riddle MC, Rosenstock J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083–1091. The largest of the three pivotal trials conducted with exenatide. The results clearly demonstrate the effects of treatment on long-term glycemic control and body weight and provide a thorough documentation of the type and severity of adverse effects.PubMedCrossRefGoogle Scholar
- 53.Degn KB, Juhl CB, Sturis J, et al.: One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53:1187–1194. Reports a comprehensive evaluation of the effects of liraglutide on islet function and whole-body glucose metabolism. The results provide a clear picture of the range of effects governed by GLP-1 mimetics.PubMedCrossRefGoogle Scholar
- 54.Madsbad S, Schmitz O, Ranstam J, et al..: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagonlike peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004, 27:1335–1342.PubMedCrossRefGoogle Scholar
- 59.Ahren B, Gomis R, Standl E, et al.: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874–2880. Reports the longest treatment experience to date with a DPP-IV inhibitor. LAF237 reduced hemoglobin A1c significantly and the effect was maintained for 1 year. Over this period, ß-cell function improved with increased insulin release seen despite lower glucose levels.PubMedCrossRefGoogle Scholar
- 60.Kim D, Wang L, Beconi M, et al.: (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1- (2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:141–151.PubMedCrossRefGoogle Scholar